In the present study, the Poria mushroom extract, PE, appears to be a promising natural oral agent capable of significantly reducing cell viability and ultimately leading to ER-induced apoptosis in human RCC, ACHN cells. Thus, PE may have potential clinical implications as an adjuvant agent/supplement offering the therapeutic option for RCC, although more studies are yet required.